These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31144763)

  • 1. Editorial Comment from Dr Hanno to Intravesical tacrolimus in treatment of intractable bladder pain syndrome/interstitial cystitis-a pilot study.
    Hanno P
    Int J Urol; 2019 Jun; 26 Suppl 1():72. PubMed ID: 31144763
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial Comment from Dr Homma to Intravesical tacrolimus in treatment of intractable bladder pain syndrome/interstitial cystitis-a pilot study.
    Homma Y
    Int J Urol; 2019 Jun; 26 Suppl 1():72. PubMed ID: 31144738
    [No Abstract]   [Full Text] [Related]  

  • 3. Intravesical tacrolimus in treatment of intractable interstitial cystitis/bladder pain syndrome - A pilot study.
    Mishra NN; Riedl C; Shah S; Pathak N
    Int J Urol; 2019 Jun; 26 Suppl 1():68-72. PubMed ID: 31144739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment from Dr. Hanno to Interstitial cystitis is bladder pain syndrome with Hunner's lesion.
    Hanno P
    Int J Urol; 2014 Apr; 21 Suppl 1():82-3. PubMed ID: 24807508
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial Comment from Dr Hanno to Hunner lesion versus non-hunner lesion interstitial cystitis/bladder pain syndrome.
    Hanno P
    Int J Urol; 2019 Jun; 26 Suppl 1():34. PubMed ID: 31144751
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial Comment from Dr Hanno to Interstitial cystitis, bladder pain syndrome, hypersensitive bladder, and interstitial cystitis/bladder pain syndrome - clarification of definitions and relationships.
    Hanno P
    Int J Urol; 2019 Jun; 26 Suppl 1():25. PubMed ID: 31144741
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment from Dr. Yoshimura to potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.
    Yoshimura N
    Int J Urol; 2014 Apr; 21 Suppl 1():56. PubMed ID: 24807499
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial Comment: Re: Hanno, P., Malykhina, A. (2014) How are we going to make progress treating bladder pain syndrome? ICI-RS 2013. Neurourol Urodyn.
    Chartier-Kastler E
    Neurourol Urodyn; 2014 Jun; 33(5):630. PubMed ID: 24729183
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment from professor Dinis to Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.
    Oliveira PD
    Int J Urol; 2014 Apr; 21 Suppl 1():56. PubMed ID: 24807498
    [No Abstract]   [Full Text] [Related]  

  • 10. Intratrigonal OnabotulinumtoxinA Improves Bladder Symptoms and Quality of Life in Patients with Bladder Pain Syndrome/Interstitial Cystitis: A Pilot, Single Center, Randomized, Double-Blind, Placebo Controlled Trial.
    Pinto RA; Costa D; Morgado A; Pereira P; Charrua A; Silva J; Cruz F
    J Urol; 2018 Apr; 199(4):998-1003. PubMed ID: 29031769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial comment from Dr. Ueda to Assessments of bladder pain syndrome/interstitial cystitis treatment in future trials.
    Ueda T
    Int J Urol; 2014 Apr; 21 Suppl 1():84. PubMed ID: 24807510
    [No Abstract]   [Full Text] [Related]  

  • 12. Editorial comment from Dr. Yoshimura to Interstitial cystitis is bladder pain syndrome with Hunner's lesion.
    Yoshimura N
    Int J Urol; 2014 Apr; 21 Suppl 1():83-4. PubMed ID: 24807509
    [No Abstract]   [Full Text] [Related]  

  • 13. Editorial comment from Dr. Hanno to Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis.
    Hanno P
    Int J Urol; 2014 Apr; 21 Suppl 1():41. PubMed ID: 24807492
    [No Abstract]   [Full Text] [Related]  

  • 14. Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome.
    Colaco M; Koslov DS; Keys T; Evans RJ; Badlani GH; Andersson KE; Walker SJ
    J Urol; 2014 Oct; 192(4):1123-9. PubMed ID: 24840534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective, Multicenter, Double-Blind, Randomized Trial of Bladder Instillation of Liposome Formulation OnabotulinumtoxinA for Interstitial Cystitis/Bladder Pain Syndrome.
    Chuang YC; Kuo HC
    J Urol; 2017 Aug; 198(2):376-382. PubMed ID: 28202358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis.
    Jhang JF; Jiang YH; Kuo HC
    Int J Urol; 2014 Apr; 21 Suppl 1():49-55. PubMed ID: 24807497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial Comment to Angiogenesis in bladder tissues is strongly correlated with urinary frequency and bladder pain in patients with interstitial cystitis/bladder pain syndrome.
    Hanno P
    Int J Urol; 2019 Jun; 26 Suppl 1():40. PubMed ID: 31144743
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence based decisions?
    Lazzeri M
    Eur Urol; 2008 Jul; 54(1):77-8. PubMed ID: 18403098
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment on: treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions?
    Novara G; Ficarra V
    Eur Urol; 2008 Jul; 54(1):76. PubMed ID: 18403095
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial comment on: treatment of bladder pain syndrome/interstitial cystitis 2008: can we make evidence-based decisions?
    Cardoso LE
    Eur Urol; 2008 Jul; 54(1):76-7. PubMed ID: 18403094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.